Welcome to our dedicated page for Satellos Bioscience SEC filings (Ticker: MSCLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Satellos Bioscience Inc. filings document a foreign issuer's clinical-stage biotechnology disclosures for SAT-3247 and its degenerative muscle disease strategy. The company's Form 6-K reports include press releases on Duchenne muscular dystrophy studies, BASECAMP and TRAILHEAD trial updates, Phase 1a/b and Phase 2 clinical and biomarker data, AAK1-targeted muscle-regeneration research, and preclinical work in facioscapulohumeral muscular dystrophy.
The filings also record investor-conference communications, Nasdaq and TSX trading references, management presentations when furnished, and formal exhibit reporting under Exchange Act Rule 13a-16 or 15d-16 for a Form 40-F filer.
Satellos Bioscience Inc. completed a public equity offering of 5,168,019 common shares and pre-funded warrants to purchase 495,049 common shares, raising about US$57.2 million in gross proceeds. The common shares were priced at US$10.10 per share, with pre-funded warrants priced at US$10.09999 each.
The company’s common shares began trading on the Nasdaq Global Market under the symbol “MSLE” and remain listed on the Toronto Stock Exchange as “MSCL.” Satellos plans to use the net proceeds mainly to fund research and development, including advancing its SAT-3247 program and other discovery and pre-clinical initiatives, as well as for working capital and general corporate purposes.
Satellos Bioscience Inc. completed a public equity offering of 5,168,019 common shares and pre-funded warrants to purchase 495,049 common shares, raising about US$57.2 million in gross proceeds. The common shares were priced at US$10.10 per share, with pre-funded warrants priced at US$10.09999 each.
The company’s common shares began trading on the Nasdaq Global Market under the symbol “MSLE” and remain listed on the Toronto Stock Exchange as “MSCL.” Satellos plans to use the net proceeds mainly to fund research and development, including advancing its SAT-3247 program and other discovery and pre-clinical initiatives, as well as for working capital and general corporate purposes.
Satellos Bioscience Inc. reported dosing the first participant in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept Phase 2 pediatric study of its oral drug SAT-3247 for Duchenne muscular dystrophy.
The trial plans to enroll 51 ambulatory children with Duchenne aged 7 to 9 years. Primary endpoints focus on safety, tolerability and effects on muscle force, while secondary endpoints assess muscle quality, function and regeneration.
SAT-3247 is described as a first-of-its-kind small molecule that targets AAK1 to help restore muscle stem cell signaling disrupted in Duchenne, and is being developed as a potential disease-modifying, dystrophin-independent treatment initially for Duchenne muscular dystrophy.
Satellos Bioscience Inc. reported dosing the first participant in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept Phase 2 pediatric study of its oral drug SAT-3247 for Duchenne muscular dystrophy.
The trial plans to enroll 51 ambulatory children with Duchenne aged 7 to 9 years. Primary endpoints focus on safety, tolerability and effects on muscle force, while secondary endpoints assess muscle quality, function and regeneration.
SAT-3247 is described as a first-of-its-kind small molecule that targets AAK1 to help restore muscle stem cell signaling disrupted in Duchenne, and is being developed as a potential disease-modifying, dystrophin-independent treatment initially for Duchenne muscular dystrophy.
Satellos Bioscience Inc., a clinical-stage biotechnology company focused on degenerative muscle diseases, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in New York City on February 12, 2026, at 10 a.m. ET.
The session will be available via live webcast on Satellos’ investor relations website, with a replay offered afterward. Company leaders will also hold one-on-one meetings with investors. Satellos highlights its lead oral small-molecule candidate SAT-3247, which targets AAK1 and is in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy.
Satellos Bioscience Inc. completed an underwritten public offering in Canada and the United States, raising approximately US$57.2 million in gross proceeds. The financing included 5,168,019 common shares, which reflects the underwriters’ full exercise of their option to purchase an additional 712,574 common shares.
Certain investors received pre-funded warrants to purchase 495,049 common shares instead of shares. Common shares were priced at US$10.10 (C$13.81) each and pre-funded warrants at US$10.09999 (C$13.80999). Satellos plans to use the net proceeds mainly for research and development, including advancing its lead candidate SAT-3247 through clinical trials, as well as for working capital and general corporate purposes.
Satellos Bioscience Inc. is launching a primary underwritten offering of common shares and pre-funded warrants in Canada and the United States under a Form F-10 and MJDS structure. The deal includes an over-allotment option for additional common shares and will deliver net proceeds to the company after underwriting commissions and expenses.
The offered shares and warrant shares are being qualified for listing on the Toronto Stock Exchange, and Satellos has also applied to list its common shares on Nasdaq under the symbol “MSLE”. Proceeds are intended to support development of SAT-3247 for Duchenne muscular dystrophy, including the BASECAMP Phase 2 pediatric study and the TRAILHEAD long-term DMD study, and to advance a planned Phase 2 trial in facioscapulohumeral muscular dystrophy. The filing highlights extensive forward-looking risks, potential PFIC tax status for U.S. investors, and the absence of a trading market for the pre-funded warrants, underscoring the speculative nature of this investment.